10 Best Forestry Stocks To Invest In 2014

A boy stands on an oil pipeline in the rainforest near Lago Agrio, Ecuador.�Source: Lou Dematteis/Redux.

At The Motley Fool, we're not just about buying�stocks --�we're about buying�businesses. And we believe the best businesses serve all of their stakeholders in the process of turning a profit. This includes investors, customers, employees, and, more generally, the world. Not too long ago, we�revealed�our favorite stakeholder-friendly companies, but�we've�also written about those that came up a bit short.

Last summer, we�discussed�an instance of irresponsible corporate behavior at�Dow Chemical� (NYSE: DOW  ) . For years, Dow has fought tooth and nail to separate itself from the Bhopal, India, chemical spill, a tragedy that took place at the hands of its subsidiary in 1984. As a financial media outlet, it is our responsibility to bring attention to these types of company issues. For this reason, we decided to dig into a similar case recently -- a decades-old Ecuadorian oil spill linked to energy giant�Chevron� (NYSE: CVX  ) . We mentioned this case briefly in our Dow article:

Top 10 Electric Utility Stocks To Invest In 2015: Silicon Motion Technology Corporation(SIMO)

Silicon Motion Technology Corporation, a fabless semiconductor company, designs, develops, and supplies a portfolio of multimedia data processing, storage, and transfer solutions primarily for consumer electronics applications. The company offers a range of microcontrollers for use in NAND flash memory storage products, including flash memory cards, USB flash drives, and embedded flash and solid state drives. It also offers a range of multimedia SoCs comprising embedded graphics processors for embedded graphics applications in desktop and notebook personal computers, game consoles, work stations, and multimedia mobile phones. In addition, the company provides semiconductor solutions consisting of mobile television tuners and integrated tuner plus demodulator SoCs for mobile phones and other portable devices; and CDMA transceivers for CDMA 1x and EVDO modem solutions, as well as transceivers for LTE modem solutions. It sells its products to module makers, original equipment manufacturers, and original design manufacturers through its direct sales force and distributors in Canada, China, Europe, Japan, Korea, Taiwan, and the United States. The company is headquartered in Jhubei City, Taiwan.

Advisors' Opinion:

• [By Travis Hoium]

  What: Shares of Silicon Motion Technology (NASDAQ: SIMO  ) fell as much as 14% today after the company released earnings.

  So what: Net sales fell 19% from the fourth quarter to $57.4 million, coming in just ahead of estimates. The real downside was on the bottom line, where earnings per share dropped more than 50%, to $0.17, $0.05 short of estimates.�

10 Best Forestry Stocks To Invest In 2014: Terra Nitrogen Company L.P.(TNH)

Terra Nitrogen Company, L.P. engages in the production and sale of nitrogen fertilizer products for agricultural and industrial applications. The company primarily offers anhydrous ammonia and urea ammonium nitrate solutions. Its customers for fertilizer products include dealers, national farm retail chains, and distributors. Terra Nitrogen GP Inc. serves as the general partner of the company. Terra Nitrogen Company, L.P. was founded in 1991 and is based in Deerfield, Illinois. Terra Nitrogen Company, LP. operates as a subsidiary of Terra Industries Inc.

Advisors' Opinion:

• [By Alex Planes]

  Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price growth. Does Terra Nitrogen (NYSE: TNH  ) fit the bill? Let's look at what its recent results tell us about its potential for future gains.

• [By Robert Rapier]

  5. Terra Nitrogen Company

  The nitrogen fertilizer MLPs were easily the worst performing MLP category, with Terra Nitrogen Company (NYSE: TNH) rounding out the five worst performers of 2013 — down 33 percent for the year. Based on the past year’s distributions, the annualized yield is 11.5 percent but, as with CVR Partners, this yield is expected to decline because of continuing weakness in the nitrogen fertilizer market.  
  

  (Follow Robert Rapier on Twitter, LinkedIn, or Facebook.)

• [By Dan Caplinger]

  Much of the pessimism about PotashCorp has come from two factors. Slower growth in key fertilizer markets China and India have held back the potash producer, as prices for the commodity have fallen from past levels. Meanwhile, lower prices for natural gas have encouraged greater use of nitrogen-based fertilizers, with Terra Nitrogen (NYSE: TNH  ) and a host of other nitrogen-fertilizer producers benefiting at the expense of PotashCorp and other potash producers.

• [By Robert Rapier] While the MLP space is dominated by the oil and gas sector, in last week’s article we began to explore some of the more exotic master limited partnership offerings. This week we continue our exploration of nontraditional MLPs by looking at the partnerships supplying fertilizer.
  
  Rentech (Nasdaq: RTK) has been around for more than a decade, and it has shifted strategies several times. Full disclosure: Rentech’s Chief Technology Officer Harold Wright is a former manager of mine when we were both at ConocoPhillips, and I have visited Rentech’s facility in Commerce City, Colorado.
  
  For most of Rentech’s existence, the company has sought to commercialize alternative fuels. At one time it had ambitions to build a large coal-to-liquids (CTL) plant, but federal legislation ultimately nudged it instead into the biomass-to-liquids (BTL) space. The company did build a BTL demonstration plant, but ultimately shut it down and has now refocused its efforts on becoming “one of the largest wood processing companies in the world.”
  
  During its interesting journey as a company, Rentech acquired two ammonia nitrogen fertilizer facilities, which turned out to be a profit center that funded the alternative energy research. In November 2011, Rentech spun off this fertilizer business into an MLP called Rentech Nitrogen Partners LP (NYSE: RNF).
  
  In the months leading to the spin-off, RTK’s market capitalization was about $200 million. Rentech maintained 60 percent ownership of RNF, and three months after the spin-off RTK’s market cap had risen to $400 million, while investors had bid RNF up to $1 billion. Interestingly, RTK’s share of RNF was worth more than RTK’s entire market cap, a situation that persists. The market currently values Rentech at $482 million, while the valuation of Rentech Nitrogen Partners makes RTK’s 60 percent stake in RNF worth slightly more than $600 million — another illu

10 Best Forestry Stocks To Invest In 2014: API Technologies Corp (ATNY)

API Technologies Corp. (API), incorporated on February 2, 1999, designs, develops and manufactures systems, subsystems, radio frequency (RF) and secure communications products, as well as provides electronics manufacturing and engineering services. Its product lines include engineered products (including unmanned aerial vehicles (UAVs), aiming systems and synthesizers), secure communications products (including TEMPEST and emanation security, encryption and secure networking products), subsystems and components (including custom hybrids, terminals, transistors and magnetics), RF and microwave products (including custom filters, amplifiers, connectors and antennas), sensors, and power systems. It operates in two segments: Systems & Subsystems, and Secure Systems & Information Assurance. In June 2013, API sold its Data Bus product line to Data Device Corporation.

The Company offers engineering services (including engineering and design for payloads, ground control systems and commercial product design) and electronics manufacturing services (EMS), such as new product introductions (NPI) and prototypes, turnkey manufacturing and printed circuit board (PCB) assembly. It operates in North America, the United Kingdom, Mexico and China.

Systems & Subsystems

The Systems & Subsystems segment includes the products and services of its operating subsidiaries Spectrum, API Defense Inc., API Defense USA Inc., API Systems Inc., SenDEC, National Hybrid Group, API Electronics, Inc., TM Systems, Keytronics, Filtran Limited and Microwave Technology, Inc. (CMT). Its products and services include RF /microwave solutions, Engineered Systems and Products, Subsystems and Hybrids, Electronics Manufacturing Services, Power Solutions, Sensors and Measurement and Engineering Services. It specializes in the development of custom Integrated Microwave Assemblies (IMAs). It develops and markets engineered systems and products, used for force protection, communication, surveillance and reconnai! ssance. Featured solutions include Unmanned Aerial Vehicles (UAVs) and systems, Unmanned Ground Vehicle (UGV) systems, aiming systems and synthesizers.

The Company�� Custom designed and off-the-shelf subsystems from API support mission critical applications, such as communication equipment, aircraft subsystems systems, computer peripherals, process control equipment, and instrumentation. Featured products include custom hybrids, terminals, transistors and magnetics solutions. It deliver Electronics Manufacturing Services (EMS), including: New Product Introductions (NPI) and prototypes, turnkey manufacturing, Printed Circuit Board (PCB) assembly, electro-mechanical assembly, systems integration, test engineering, turnkey box build and supply chain services. Its power products offer commercial and defense customer�� superior power and energy efficiency. Products span power systems management, distribution, and panels, and custom-designed power supplies for defense and aerospace applications.

The Company offers a range of precision sensors and control products, including position sensing solutions for precision guided munitions, gyros, accelerometers, and inertial measurement sensors for defense and aerospace applications, and position and temperature sensors for industrial and commercial applications. It offers a range of design and engineering services for both defense and commercial customers. Featured areas of expertise include payloads, ground control systems, RF, microwave and millimeterwave.

Secure Systems & Information Assurance

The Secure Systems & Information Assurance segment includes the products and services of its subsidiaries Cryptek, Emcon Emanation Control Inc., Secure Systems and Technologies and the Ion Networks division. API offers customers various secure network and hardware solutions, including Emanation Security, Tempest and secures network access, ruggedized systems and secure networking products. Its products are marketed u! nder the ! Cryptek, ION, Emcon, SST and Netgard brand names. These product offerings are sold to governments and other international organizations that require the level of security in the areas of identity validation, network access management, TEMPEST network intrusion prevention, and secure and encrypted fax, computers and telephones.

The Company�� products and services include Emanation Security and TEMPEST Products, Secure Networking Products, Encryption and Professional Services. The Company�� emanation security products include computing systems, network and communications systems and office systems. Its security appliances and software intelligently enables secure information sharing and systems management across organizations and technologies. Service providers, IT and communications equipment manufacturers, enterprises and government agencies rely on its secure networking products for secure systems for remote management, database guards for secure information sharing and secure virtual enclaves.

The Company�� encryption products and services enable Federal, State and Local governments, Department of Defense agencies, the Department of Homeland Security and the Armed Services to interoperate securely across organizational boundaries and untrusted systems. Its professional services include information assurance and secure networking architecture and design solutions, emanation security testing and engineering and security certification and validation.

The Company competes with Aeroflex, Incorporated, Anaren Inc., Data Devices Inc., Kratos Defense & Security Solutions, Inc., DRS.Finmeccanica, Ducommun Incorporated, Cobham plc, Comtech EF Data Corp. and M/A-COM Technology Solutions Inc.

Advisors' Opinion:

• [By Laura Brodbeck]

  Thursday

  Earnings Expected From: Lindsay Corporation (NYSE: LNN), Emmis Communications Corporation (NASDAQ: EMMS), API Technologies Corp. (NASDAQ: ATNY) Economic Releases Expected: Australian unemployment rate, Japanese consumer confidence, French industrial output, Italian industrial output, Bank of England interest rate decision, US initial and continuing jobless claims

  Friday

• [By Anna Prior]

  API Technologies Corp.(ATNY) said it has received a new order to supply high-power amplifier systems as part of a Defense Department maritime requirement. This initial order is part of a multimillion-dollar program with first production delivery set for May 2015, the company said. Shares jumped 6% to $2.81 premarket.

10 Best Forestry Stocks To Invest In 2014: Southern Cross Exploration NL (SXX)

Southern Cross Exploration NL is an Australia-based company engaged in the investment in the Bigrlyi Uranium Joint Venture, on which pre-development investigations and further drilling were carried out; exploration for gold and minerals, reviews of opportunities for participation in and/or acquisition of mineral exploration and mining ventures, and examination of projects in respect of different commodities, share investments, loans and other securities. The Bigrlyi project is located in the Ngalia Basin, northwest of Alice Springs, in the Northern Territory. The Company's interest in the Bigrlyi Uranium Joint Venture is one of its assets, in joint venture with two multi-billion dollar companies, CGNPC - via the Operator, Energy Metals Ltd (EME) - and Paladin Energy Ltd (PDN). Advisors' Opinion:

• [By idahansen]

  Due to the impact of The Great Recession, stocks in the agricultural sector such as Caterpillar (NYSE: CAT), The Mosiac Company (NYSE: MOS), and Potash of Saskatchewan (NYSE: POT) are trading well below highs. The exchange traded fund for the industry, DBA Power Shares, (NYSE: DBA), is down more than 17% for the last year. Despite this bearish trend, legendary investors such as Warren Buffett, George Soros, and Jim Rogers are very positive for the agriculture group. With the long term bullish outlook for the sector from the greatest investors in history, small cap stocks active in the fertilizer sector such as Sirius Minerals (LSE: SXX) and Americas Petrogas (TSX: BOE) are especially attractive.

10 Best Forestry Stocks To Invest In 2014: TearLab Corporation(TEAR)

TearLab Corporation operates as an ophthalmic device company. It engages in developing and commercializing TearLab Osmolarity System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease. The company?s system enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, which is a single-use microfluidic microchip; TearLab pen, which is a hand-held device that interfaces with the TearLab disposable; and TearLab reader, which is a small desktop unit that allows for the docking of the TearLab disposable and the TearLab pen, as well as provides a quantitative reading for the operator. TearLab Corporation markets its system through a network of distributors in North America, Europe, and Asia. The company, formerly known as OccuLogix, Inc., was founded in 1996 and is headquart ered in San Diego, California.

Advisors' Opinion:

• [By Roberto Pedone]

  One potential earnings short-squeeze candidate is in-vitro diagnostic player TearLab (TEAR), which is set to release numbers on Tuesday after the market close. Wall Street analysts, on average, expect TearLab to report revenue of $3.51 million on a loss of 13 cents per share.

  This company has managed to top Wall Street estimates two times over the last four quarters, which is a bullish earnings trend. If TearLab can delve another beat, then shares could be setting up for a large move higher.

  The current short interest as a percentage of the float for TearLab is extremely high at 37.1%. That means that out of the 25.54 million shares in the tradable float, 8.59 million shares are sold short by the bears. This is a huge short interest on a stock with a very low tradable float. If the bulls get the earnings news they're looking for, then shares of TEAR could easily explode higher post-earnings as the bears jump to cover some of their bets.

  From a technical perspective, TEAR is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last six months, with shares moving higher from its low of $5.26 to its recent high of $15.18 a share. During that uptrend, shares of TEAR have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of TEAR within range of triggering a major breakout trade post-earnings.

  If you're bullish on TEAR, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $14.28 to its 52-week high at $15.18 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 942,598 shares. If that breakout hits, then TEAR will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside

• [By Seth Jayson]

  TearLab (Nasdaq: TEAR  ) reported earnings on May 13. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), TearLab beat expectations on revenues and exceeded expectations on earnings per share.

10 Best Forestry Stocks To Invest In 2014: Radiant Creations Group Inc (RCGP)

Radiant Creations Group, Inc., formerly Nova Mining Corporation, incorporated on December 29, 2005, is an exploration-stage Company. The Company�� principal business is the acquisition and exploration of mineral resources.

As of February 28, 2013, the Company has not determined whether its mineral claims contain reserves that are economically recoverable. During the fiscal 2013, the Company had not generated any revenue.

Advisors' Opinion:

• [By Peter Graham]

  What�� the Catch With Axxess Pharma Inc? According to various disclosures, transactions of $2.5k, $3k, $4k, $14k, $25k, $50k and $85k have or will occur to mention Axxess Pharma Inc in various investment newsletters plus the company has been busy announcing new deals. Last Wednesday, Axxess Pharma Inc announced it had signed term sheet from TCA Global Credit Masters Fund to secure a $4 million revolving line of credit which was expected to close within 14 days pending final due diligence. The press release stated the revolving line of credit would enable Axxess Pharma to ��enerate significant revenue in the near-term with high gross profit margins��plus the deal was expected to be the beginning of a long-term long-term partnership between the two companies. Last Monday, Axxess Pharma Inc also announced an exclusive agreement providing them the world-wide exclusive rights to develop, market and sell a line of pain relief and muscle recovery products, as well as develop and market a vitamins and minerals line under the TapouT brand name; while back in September, the company announced an agreement for the acquisition of the assets of Revive Bioscience Inc. - a leading Canadian OTC healthcare company. However, a quick look at both Google Finance and Yahoo! Finance reveals no financials for Axxess Pharma Inc ��meaning its investor beware.

  Radiant Creations Group Inc (OTCBB: RCGP) Is Launching Its Direct to Consumer Sales Model

  Small cap Radiant Creations Group Inc says it has achieved exciting breakthroughs creating remarkable products in skin protection and hydration, anti-aging, liver health and weight balance by combining DNA technologies developed in the Western World and naturally acting traditional Chinese medicine ingredients believed to be never before used in western culture by any bioscience company. On Friday, Radiant Creations Group Inc fell 9.1% to $0.20 for a market cap of $6 million plus RCGP is up 53.85 ov

10 Best Forestry Stocks To Invest In 2014: Quest Diagnostics Inc (DGX)

Quest Diagnostics Incorporated (Quest Diagnostics), incorporated in 1990, is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. Its diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. On April 4, 2011, the Company acquired Athena Diagnostics (Athena). On May 17, 2011, the Company acquired Celera Corporation (Celera). In January 2012, the Company acquired S.E.D. Medical Laboratories. In December 2012, the Company sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the ! assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.

Clinical Testing

The Company is a commercial clinical testing company. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. The Company offers customers the access to the test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.

The Company is a provider of routine clinical testing, including testing for drugs of abuse. The Company performs routine testing through its network of laboratories and rapid response laboratories. The Company also performs routine testing at hospital laboratories that the Company manages. The Company operates laboratories round the clock. The majority of test results are delivered electronically. Routine tests measure various bodily health parameters, such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include blood chemistries, including cholesterol levels; complete blood cell counts; urinalysis; pregnancy and other prenatal tests, and routine microbiology testing.

The Company is a provider of anatomic pathology services in the United States, through its AmeriPath, Dermpath Diagnostics and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. The Company provides inpatient anatomic pathology and medical director services at hospitals throughout the country, and through ! its labor! atories. The Company provides a range of services to all anatomic pathology subspecialties. The Company provides integrated, reports that include both anatomic pathology and clinical pathology tests, enabling its pathologists to offer patients and physicians a complete analysis. The Company introduced the Leumeta family of tests for leukemia and lymphoma.

The Company is a provider in the United States of gene-based and esoteric testing. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, genetic tests, autoimmune panels and complex cancer evaluations. During the year ended December 31, 2011, it acquired Athena Diagnostics, a provider of neurology testing. Its esoteric laboratories provide reference testing services to physicians, academic medical centers, hospitals and other commercial laboratories. The Company also offers gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. The Company develops tests at its laboratories, such as Quest Diagnostics Nichols Institute. It also develops techniques and services in anatomic pathology.

In 2011, the Company introduced its melanoma treatment selection mutation panel, which is designed to assist in the personalized selection of patient therapies. The Company introduced its thyroid cancer mutation panel, which assists in the diagnosis of thyroid cancer and aids physicians and surgeons as they plan surgery and other therapies to treat and attempt to cure thyroid cancer. During 2011, it enhanced its SureSwab Vaginosis/Vaginitis Plus test. The Company introduced Accutype IL28b, a test designed to aid in the prediction of patient response to peginterferon alpha-based therapy for treating hepatitis C virus infection. In 2011, it introduced testing for very long chain fatty acids, to assist in diagnosis and monitori! ng of inh! erited disorders of fatty acid metabolism. It also introduced high resolution chromosomal analysis testing with oligonucleotide microarrays to enhance its testing services in the pre-natal and post-natal genetics areas. During 2011, the Company released a test for therapeutic drug monitoring of dabigatran, an oral anti-coagulant. The Company also released genetic testing for SLC01B1, which helps identify patients at risk for myopathy from Simvastatin therapy for cholesterol reduction. Through Athena Diagnostics, it launched several molecular genetic tests for stroke, neuromuscular diseases and mitochondrial disorders.

Healthcare Information Technology

The Company provides interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly information technology (IT) implementation or workflow disruption, including through its Care360 suite of products and its ChartMaxx electronic document management system for hospitals. These solutions offer access to a national healthcare provider network, including approximately 200,000 networked physicians and clinicians using Quest Diagnostics��Care360 connectivity products. The Care360 products, including its Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. As of December 31, 2011, prescriptions were written through Care360 ePrescribing at an annualized rate of 32 million medications. Using its Care360 connectivity products, physicians can securely provide diagnostic and other data to a patient�� account. It offers Gazelle, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone.

Clinical Trials Testing

The Company is a provider of central l! aboratory! testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It has clinical trials testing centers in the United States and the United Kingdom, and it provides clinical trials testing in Argentina, Australia, Brazil, the People�� Republic of China and Singapore through affiliated laboratories. The Company has biomarker capabilities. In 2011, it acquired Celera, enhancing its ability to provide biomarker discovery and develop IVD test kits.

Life Insurer Services

The Company is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies doing business in many countries outside the United States. Its risk assessment services comprise underwriting support services to the life insurance industry, including laboratory testing, electronic data collection, specimen collection and paramedical examinations, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The laboratory tests that it performs and data it gathers are designed to assist insurance companies to objectively evaluate the mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance applicants, but also includes specimens of applicants for other types of insurance. Most of its specimen collections and paramedical examinations are performed by its network of approximately 5,000 contracted paramedical examiners at the applicant�� home or workplace. The Company also offers paramedical examinations through approximately 500 of its patient service centers, and operate approximately 80 locations other than patient service centers in the United States and Canada where the Company provides paramedical examinations, bringing to approximately 580 the total number of sites where it can provide these examinations. The Company also contracts with third parties at over! an addit! ional 200 locations globally to coordinate providing these exams.

Employer Services

The Company is a provider of testing to employers for the detection of employee use of drugs of abuse. Its Quest Diagnostics Drug Testing Index, which is an annual report of its aggregate drug testing results, is used by employers, the federal government and the media to help identify and quantify drug abuse among the nation�� workforce. It provides a range of solutions for drugs of abuse, including urine, hair, blood and oral fluid tests. In 2011, it introduced Oral-Eze, its own oral fluid collection system that simplifies the collection of oral samples for routine drug testing. The Oral-Eze Oral Fluid Collector provides all the advantages of previous collection systems, with the added benefit of its indicator window technology. The Company provides wellness testing and analytic services to employers.

Diagnostic Products

Diagnostic Products include point-of-care, or near-patient and testing. The Company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care, or near-patient, testing for the professional market. The Company has several companies, including Focus Diagnostics, HemoCue and Celera. Focus Diagnostics is a provider of infectious disease testing. Focus Diagnostics develops, manufactures and markets diagnostic products, such as HerpeSelect ELISA tests that detect patient antibodies to specific types of herpes simplex virus, which can be performed on a variety of instrument platforms. Focus Diagnostics sells its diagnostic products to academic medical centers, hospitals and commercial laboratories globally. Focus Diagnostics has an agreement with 3M Corporation for global human diagnostic rights to a compact integrated bench-top instrument for use with real time polymerase chain reaction (PCR) assays. These tests are sold under the Simplexa brand name. In 2011, Focus Diagnostic! s receive! d the CE mark to offer Simplexa tests in Europe, including tests for Cytomegalovirus, Epstein Barr virus, BK virus and clostridium difficile. Focus Diagnostics offers molecular transplant-testing menus in Europe.

HemoCue manufactures and distributes point-of-care testing products globally. HemoCue is a global provider in point-of-care testing for hemoglobin, with a growing market share for glucose, microalbumin and white blood cell testing. HemoCue offers its White Blood Cell Differential System in Europe. Celera offers complexity molecular diagnostic products in segments, such as HIV-1 drug resistance testing, reproductive genetics, transplantation and cardiovascular genetics. It also manufactures and offers the InSure fecal immunochemical test (FIT) for screening for colorectal cancer.

The Company competes with Laboratory Corporation of America Holdings, Inc.

Advisors' Opinion:

• [By Mark Hulbert]

  The stocks are C.H. Robinson Worldwide (CHRW) �, a freight-transportation company; chip maker Cirrus Logic (CRUS) �; independent oil company Forest Oil (FST) �; investment bank Greenhill & Co. (GHL) �; Intrepid Potash (IPI) �, a fertilizer company; retailer J.C. Penney (JCP) �; Quest Diagnostics (DGX) �, a medical diagnostic company; Strayer Education (STRA) �, a for-profit college; Tower Group International (TWGP) �, an insurance company; and Windstream Holdings (WIN) �, a rural telecommunications firm.